Ceftriaxone Sodium for Injection

This product is a first-generation cephalosporin with a broad antibacterial spectrum and strong activity against Gram-positive bacteria. Penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, Group B hemolytic Streptococcus, Streptococcus viridans, Staphylococcus epidermidis, Corynebacterium diphtheriae, and Bacillus anthracis are all quite sensitive to this product. Enterococci, methicillin-resistant Staphylococcus, Listeria, and Nocardia are resistant. Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis, and Neisseria gonorrhoeae are highly sensitive to this product. Some strains of Escherichia coli, Klebsiella, Salmonella, Shigella, and Proteus are moderately sensitive to this product, while most of the other Gram-negative rods are resistant. Gram-positive anaerobic bacteria are sensitive to this product, and Bacteroides fragilis is resistant to this product. This product mainly inhibits the synthesis of bacterial cell walls.

Ceftriaxone Sodium

This product is white or off-white crystalline powder.

It is used for sepsis, lower respiratory tract infection, abdominal and biliary tract infection, complicated urinary tract infection and severe skin and soft tissue infection caused by sensitive Gram-negative bacilli. It is especially suitable for infections in immunocompromised patients caused by multiple drug-resistant Gram-negative bacilli, hospital-acquired infections, and central nervous system infections caused by Gram-negative bacilli or Pseudomonas aeruginosa.

Intravenous injection or intravenous drip. 1. For sepsis, lower respiratory tract infection, biliary tract infection, etc., 4-6g a day, divided into 2-3 intravenous drips or intravenous injections, the course of treatment is 10-14 days; 2. For urinary tract infection and severe skin and soft tissue infection, 2-4g a day, divided into 2 intravenous drips or intravenous injections, the course of treatment is 7-14 days. 3. For certain life-threatening infections, severe Pseudomonas aeruginosa infections and central nervous system infections, the dosage can be increased to 0.15-0.2g/kg a day, divided into 3 intravenous drips or intravenous injections. 4. The common dose for infants and young children is 30-100mg/kg a day, divided into 2-3 intravenous drips.

The adverse reactions of this product are rare and mild. A small number of patients may experience rash, itchy skin, drug fever; nausea, diarrhea, abdominal pain; mild phlebitis at the injection site; occasional transient increase in serum aminotransferase, blood urea nitrogen, and blood creatinine; leukopenia, thrombocytopenia, and eosinophilia, etc.

It is contraindicated in patients who are allergic to cephalosporin antibiotics.

Precautions during pregnancy and lactation: Use with caution in lactating women.

1. This product is contraindicated with the following drugs: amikacin sulfate, gentamicin, kanamycin, tobramycin, neomycin, chlortetracycline hydrochloride, tetracycline hydrochloride, oxytetracycline hydrochloride, colistin sodium methanesulfonate, polymyxin B sulfate, erythromycin gluconate, erythromycin lactobionate, lincomycin, sulfisoxazole, aminophylline, soluble barbiturates, calcium chloride, calcium glucoheptonate, diphenhydramine hydrochloride and other antihistamines, lidocaine, norepinephrine, metaraminol, methylphenidate, succinylcholine, etc. Occasionally, it may also be contraindicated with the following drugs: penicillin, methicillin, hydrocortisone succinate, phenytoin sodium, prochlorperazine, vitamin B group and vitamin C, hydrolyzed protein. 2. The stability in sodium bicarbonate solution is worse than in other solutions. 3. This product cannot be administered in the same container with aminoglycoside antibiotics. Precipitation may occur when mixed with vancomycin. 4 When this product is used in combination with aminoglycoside antibiotics or strong diuretics such as furosemide, renal function must be closely monitored to avoid the occurrence of renal damage.

Sealed, store in a cool dark place

1.0g

Qilu Antibiotics Pharmaceutical Co., Ltd.

• Founded in:

  1995-05-29

• Address:

  No. 849, Dongjia Street, Licheng District, Jinan City, Shandong Province

• Tax NO.:

  91370100614074047M

• Registered Funds:

  $86 million

• Website:

  Log in to view

• Email:

  Log in to view